W
WAVEMAN · COMPANY
SBFM · Sunshine Biopharma Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

SBFM

Sunshine Biopharma Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001402328
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
5
13F, latest reported quarter
REVENUE GROWTH
+4.1%
XBRL, annual
NET MARGIN
-16.5%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
5 funds added or opened last quarter
below 96% of Pharma & Biotech
REVENUE
+4.1% year over year
more than 52% of Pharma & Biotech
MARGIN
-16.5% net margin
more than 52% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -92.1%
-92.1%12M
-92%-44%+4%+53%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Sunshine Biopharma Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Slilaty Steve N.
Chief Executive Officer
BUY
2024-03-04
100,000.0
$10.0K
Slilaty Steve N.
Chief Executive Officer
BUY
2024-02-08
20,000.0
$2.0K
Sebaaly Camille
CFO/Secretary
BUY
2022-11-30
30,000.0
$22.8K
Sebaaly Camille
CFO/Secretary
BUY
2022-06-03
25,000.0
$30.5K
4 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
JANE STREET GROUP, LLC
14,974.0 sh
$31.4K
MORGAN STANLEY
385.0 sh
$808
UBS Group AG
11,879.0 sh
$546
SBI Securities Co., Ltd.
162.0 sh
$340
Clear Street Group Inc.
449.0 sh
$27
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$36.3M$34.9M$24.1M$4.3M
GROSS PROFIT$12.3M$10.7M$8.3M$1.7M
OPERATING INCOME$-6.2M$-5.8M$-4.8M$-27.0M
NET INCOME$-6.0M$-5.1M$-4.5M$-26.7M
EPS (DILUTED)-7.32-351.36-1.76
OPERATING CASH FLOW$-5.3M$-12.5M$-8.8M$-5.2M
CASH$21.8M
BUYBACKS$0$3.1M$541.1K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →